January 30, 2008 - Aethlon Medical Inc., a developer of therapeutic devices for infectious disease and advanced blood filtration, and Delcath Systems Inc., a company focused on developing a drug delivery system, today announced a collaboration to jointly research and develop an advanced filtration cartridge for potential use in Delcath Systems' percutaneous hepatic perfusion (PHP) system, a technology designed to isolate and deliver high doses of anti-cancer agents to specific organs or regions of the body, while minimizing the exposure of the drugs to the rest of the body.
“We continue seeking ways to improve and extend the applications for Delcath’s platform technology,” said Delcath president and CEO Richard Taney. “Recent advances in filtration technologies make this an area of focus for our company as we seek to expand the potential applications for the Delcath System. Activated carbon is a very efficient broad-spectrum filter medium for the majority of anti-cancer agents, but we continue to investigate novel technologies that will enable physicians to use our system with additional drugs.”
For more information: www.delcath.com